



**BlueCross  
BlueShield**

Federal Employee Program

## AVMAPKI FAKZYNJA CO-PACK

### PRIOR APPROVAL REQUEST

Additional information is required to process your claim for prescription drugs. Please complete the cardholder portion, and have the prescribing physician complete the physician portion and submit this completed form.

Send completed form to:  
Service Benefit Plan  
Prior Approval  
P.O. Box 52080 MC 139  
Phoenix, AZ 85072-2080  
Attn: Clinical Services  
Fax: 1-877-378-4727

Patient Information (required)				Provider Information (required)			
Date:				Provider Name:			
Patient Name:				Specialty:		NPI:	
Date of Birth:		Sex: <input type="checkbox"/> Male <input type="checkbox"/> Female		Office Phone:		Office Fax:	
Street Address:				Office Street Address:			
City:		State:	Zip:	City:		State:	Zip:
Patient ID: <b>R</b>				Physician Signature:			
<b>PHYSICIAN COMPLETES</b>							

## Avmapki Fakzynja Co-pack (avutometinib/defactinib)

\*\*Check [www.fepblue.org/formulary](http://www.fepblue.org/formulary) to confirm which medication is part of the patient's benefit

**NOTE:** Form must be completed in its **entirety** for processing

Is this request for brand or generic? ☐ Brand ☐ Generic

Will the patient need more than 3 cartons every 84 days? ☐ Yes\* ☐ No

**\*If YES**, please specify the requested quantity: \_\_\_\_\_ cartons every 84 days

1. Does the patient have a diagnosis of recurrent low-grade serious ovarian cancer (LGSOC)? ☐ Yes ☐ No

2. Has the patient been on this medication continuously for the last **6 months**, excluding samples? **Please select answer below:**

☐ **NO** – this is **INITIATION** of therapy, please answer the following questions:

a. Is there a presence of a KRAS mutation in tumor specimens? ☐ Yes ☐ No

b. Has the patient received prior systemic therapy? ☐ Yes ☐ No

☐ **YES** – this is a PA renewal for **CONTINUATION** of therapy, please answer the following question:

a. Has the patient experienced disease progression or unacceptable toxicity? ☐ Yes ☐ No

3. Does the prescriber agree to monitor for ocular toxicities? ☐ Yes ☐ No

4. **FEMALE Patient:** Is the patient of reproductive potential? ☐ Yes\* ☐ No

**\*If YES**, will the patient be advised to use effective contraception during treatment with Avmapki Fakzynja Co-pack and for 1 month after the last dose? ☐ Yes ☐ No

5. **MALE Patient:** Does the patient have a female partner of reproductive potential? ☐ Yes\* ☐ No

**\*If YES**, will the patient be advised to use effective contraception during treatment with Avmapki Fakzynja Co-pack and for 4 months after the last dose? ☐ Yes ☐ No